These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1311 related articles for article (PubMed ID: 26855278)

  • 1. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA.
    Ferreira A; Sagkriotis A; Olson M; Lu J; Makin C; Milnes F
    PLoS One; 2015; 10(7):e0133968. PubMed ID: 26208030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration.
    Johnston SS; Wilson K; Huang A; Smith D; Varker H; Turpcu A
    Adv Ther; 2013 Dec; 30(12):1111-27. PubMed ID: 24310208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration.
    Seong HJ; Park YM; Kim J; Son KJ; Chung EJ
    Korean J Ophthalmol; 2022 Oct; 36(5):435-442. PubMed ID: 35989065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS; Muecke J
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.
    Lotery AJ; Regnier S
    Eye (Lond); 2015 Mar; 29(3):380-7. PubMed ID: 25572584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.